TAMs can target CD8+ T cells and inhibit immune rejection of tumor cells through various mechanisms (46), while IL-12 secreted by M1 cells can activate CD8+ T cells to stimulate an anti-tumor response in solid tumor models (47, 48). This evidence concerns the gene CD8A and neoplasm.